W
William C. Hahn
Researcher at Harvard University
Publications - 515
Citations - 85047
William C. Hahn is an academic researcher from Harvard University. The author has contributed to research in topics: Cancer & Medicine. The author has an hindex of 130, co-authored 448 publications receiving 72191 citations. Previous affiliations of William C. Hahn include Brigham and Women's Hospital & University of Washington.
Papers
More filters
Journal ArticleDOI
Germline cancer susceptibility gene variants, somatic second hits, and survival outcomes in patients with resected pancreatic cancer
Matthew B. Yurgelun,Matthew B. Yurgelun,Anu Chittenden,Vicente Morales-Oyarvide,Douglas A. Rubinson,Douglas A. Rubinson,Richard F. Dunne,Margaret M. Kozak,Zhi Rong Qian,Marisa W. Welch,Lauren K. Brais,Annacarolina da Silva,Justin L. Bui,Chen Yuan,Tingting Li,Wanwan Li,Atsuhiro Masuda,Mancang Gu,Andrea J. Bullock,Daniel T. Chang,Thomas E. Clancy,David C. Linehan,Jennifer J. Findeis-Hosey,Leona A. Doyle,Aaron R. Thorner,Matthew D. Ducar,Bruce M. Wollison,Natalia Khalaf,Kimberly Perez,Kimberly Perez,Sapna Syngal,Sapna Syngal,Andrew J. Aguirre,William C. Hahn,William C. Hahn,Matthew Meyerson,Charles S. Fuchs,Charles S. Fuchs,Charles S. Fuchs,Shuji Ogino,Jason L. Hornick,Aram F. Hezel,Albert C. Koong,Albert C. Koong,Jonathan A. Nowak,Jonathan A. Nowak,Brian M. Wolpin,Brian M. Wolpin +47 more
TL;DR: Nearly 10% of PDAC patients harbor germline variants, although the majority lack somatic second hits, the therapeutic significance of which warrants further study.
Journal ArticleDOI
A functional landscape of resistance to ALK inhibition in lung cancer.
Frederick H. Wilson,Frederick H. Wilson,Cory M. Johannessen,Federica Piccioni,Pablo Tamayo,Jong Wook Kim,Jong Wook Kim,Eliezer M. Van Allen,Eliezer M. Van Allen,Steven M. Corsello,Steven M. Corsello,Marzia Capelletti,Antonio Calles,Mohit Butaney,Tanaz Sharifnia,Tanaz Sharifnia,Stacey Gabriel,Jill P. Mesirov,William C. Hahn,William C. Hahn,Jeffrey A. Engelman,Matthew Meyerson,Matthew Meyerson,Matthew Meyerson,David E. Root,Pasi A. Jänne,Levi A. Garraway,Levi A. Garraway +27 more
TL;DR: In this article, the authors conducted a large-scale functional genetic study to characterize mechanisms of resistance to ALK inhibition in ALK-dependent lung cancer cells, identifying members of known resistance pathways and additional putative resistance drivers.
Journal ArticleDOI
Genomic alterations link Rho family of GTPases to the highly invasive phenotype of pancreas cancer
Alec C. Kimmelman,Aram F. Hezel,Andrew J. Aguirre,Hongwu Zheng,Jihye Paik,Haoqiang Ying,Gerald C. Chu,Jean X. Zhang,Ergun Sahin,Giminna Yeo,Aditya H. Ponugoti,Roustem Nabioullin,Scott Deroo,Shenghong Yang,Xiaoxu Wang,John P. McGrath,Marina Protopopova,Elena Ivanova,Jianhua Zhang,Bin Feng,Ming-Sound Tsao,Mark Redston,Alexei Protopopov,Yonghong Xiao,P. Andrew Futreal,William C. Hahn,David S. Klimstra,Lynda Chin,Lynda Chin,Ronald A. DePinho +29 more
TL;DR: It is determined that RIOK3 promotes its invasive activities through activation of the small G protein, Rac, which prompted a genome wide survey of other components of the Rho family network, revealing p21 Activated Kinase 4 (PAK4) as another amplified gene in PDAC tumors and cell lines.
Journal ArticleDOI
Role of Telomeres and Telomerase in the Pathogenesis of Human Cancer
TL;DR: Recent advances in understanding of telomere biology indicate that the manipulation oftelomeres and telomerase will lead to clinically significant applications in the diagnosis, prevention, and treatment of neoplastic disease.
Journal ArticleDOI
The current state of preclinical prostate cancer animal models.
Kenneth J. Pienta,Cory Abate-Shen,David B. Agus,Ricardo M. Attar,Leland W.K. Chung,Norman M. Greenberg,William C. Hahn,John T. Isaacs,Nora M. Navone,Donna M. Peehl,Jonathon W. Simons,David B. Solit,Howard R. Soule,Terry A. VanDyke,Michael J. Weber,Lily Wu,Robert L. Vessella +16 more
TL;DR: The PCMWG reviewed the state of prostate cancer preclinical models and identified the current limitations of cell line, xenograft and genetically engineered mouse models that have hampered the transition of scientific findings from these models to human clinical trials.